Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

Head and Neck Cancer Clinical Trial

Official title:

A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05820711
• Other study ID #: 2023-0194
• Secondary ID: UW21144SMPH/HUMA
• Status: Recruiting
• Phase: Phase 1
• Start date: July 17, 2023
• Est. completion date: March 31, 2026

Study information

• Verified date: February 2024
• Source: University of Wisconsin, Madison
• Contact: Cancer Connect
• Phone: 800-622-8922
• Email: clinicaltrials[@]cancer.wisc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical research study is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stem cells (MSCs) into your salivary glands.

Participants will have head and neck cancer that was treated with radiation therapy, and in this study will:

• Undergo a collection of bone marrow using a needle;

• Donate saliva;

• Undergo a salivary gland ultrasound; and,

• Complete questionnaires that ask about dry mouth

Participants can expect to be in this study for up to 30 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 31, 2026
• Est. primary completion date: March 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• History of histological diagnosis of head and neck cancer (HNC) that was treated with radiation therapy and currently clinically or radiologically no evidence of disease (NED)

• Xerostomia, defined as patient reported salivary function (pre-treatment) = 80% of healthy (pre-radiation)

• = 18 years of age, = 90 years of age.

• Patients = 2 years from completion of radiation therapy for HNC

• Karnofsky performance status = 70, patient eligible for bone marrow aspirate with wakeful anesthesia

• Willing and able to give informed consent

• Radiographically confirmed submandibular gland(s)

Exclusion Criteria:

• Salivary gland disease (i.e., sialolithiasis)

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms
• Xerostomia

Intervention

Drug:
• MSC
Injection of MSCs into submandibular glands at pre-specified dose level: Dose -1: 5 (4 - 6) x10^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml) Dose 0: 10 (8 - 12) x10^6 MSCs per gland (1 ml) Dose 1: 20 (16 - 24) x10^6 MSCs per gland (2 ml)

Locations

Country	Name	City	State
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability: Determination of Recommended Phase 2 Dose (RP2D)	RP2D (also called the maximum tolerated dose) of MSCs determined by the proportion of subjects experiencing dose limiting toxicity (DLT)	Up to 1 month post-injection
Primary	Safety and Tolerability: Number of subjects with pain >5 on a 0-10 point scale	Incidence of pain assessed as greater than 5 on standard 0-10 point pain scale (0=not at all to 10=worst pain imaginable)	1 month post-injection
Primary	Safety and Tolerability: Number of Serious Adverse Events	Incidence of any serious adverse event	Up to 1 month post-injection
Primary	Safety and Tolerability: Number of Treatment-Emergent Pre-Specified Adverse Events	Incidence of pre-specified adverse events	Up to 1 month post-injection
Secondary	Change in Quality of Life	Efficacy of MSC assessed through University of Michigan Xerostomia Related Quality of Life (XeQOL) scale, which is a 15-item assessment scale with 4 domains. The score is the average of all responses of all domains and can range from 0 to 4, where higher scores indicate increased xerostomia burden.	Baseline to 24 months post-injection
Secondary	Change in Quality of Life	Efficacy of MSC assessed through the MD Anderson Dysphagia Index (MDADI), which is a 20-item questionnaire designed for evaluating the impact of dysphagia (swallowing ability). Scores range from 20 (extremely low functioning) to 100 (high functioning).	Baseline to 24 months post-injection
Secondary	Change in Quality of Life	Efficacy of MSC assessed through VAS xerostomia questionnaire, which is an 8-item questionnaire that measures the perception of dry mouth. Scores range from 0-10, with 0 being low dryness and 10 being high dryness.	Baseline to 24 months post-injection
Secondary	Change in salivary production	Saliva production will be measured by having participants chew inert gum base to the pace of a metronome (70 beats per minute) while expectorating saliva (without swallowing) into the saliva collection aid for 5 minutes total40. Cryovials will be weighed before and after collection and the difference in weight (g) will represent the amount of saliva produced in 5 minutes for each condition.	Baseline to 24 months post-injection
Secondary	Shear wave velocity with acoustic radiation force impulse	Assess imaging characteristics of submandibular glands after MSC, measured by ultrasound	3, 6, and 12 months post-injection